Puma Biotechnology, Inc. (PBYI)
| Market Cap | 149.54M |
| Revenue (ttm) | 226.63M |
| Net Income (ttm) | 15.38M |
| Shares Out | 48.24M |
| EPS (ttm) | 0.32 |
| PE Ratio | 9.69 |
| Forward PE | 8.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 846,865 |
| Open | 3.250 |
| Previous Close | 3.280 |
| Day's Range | 3.050 - 3.340 |
| 52-Week Range | 2.130 - 7.730 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+125.81%) |
| Earnings Date | Aug 1, 2024 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2023, PBYI's revenue was $235.64 million, an increase of 3.34% compared to the previous year's $228.03 million. Earnings were $21.59 million, an increase of 1079450.00%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the...
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
Puma Biotechnology to Join Russell 3000 Index
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will report its financial results for 1Q-2024 after the close and host a conference call at 1:30 p.m. PT on May 2.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released it's fourth quarter and full year 2023 earnings and will host a conference call to discuss operating results and outlook.
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that it had initiated ALISCA-Lung1, a Phase II clinical trial of alisertib in small cell lung cancer.
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the design of the Phase 2 alisertib trial for treatment of HER2-, HR+ metastatic breast cancer (PUMA-ALI-1201).
Puma Biotechnology Reports Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its Q3-2023 earnings release on Nov. 2, 2023, and hosted a conference call to discuss the results of the quarter.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 2, 2023, following the release of its 3Q-2023 results.
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting.
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 2Q'23 earnings release on Aug. 3 and hosted a call at 4:30 pm ET to discuss results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its financial results for the first quarter of 2023 after market close, followed by a conference call, on May 4, 2023.
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
LOS ANGELES--(BUSINESS WIRE)--Results of Puma's Phase II TBCRC041 trial of alisertib in patients with endocrine-resistant advanced breast cancer published online in JAMA Oncology.